Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(21 sites)

United States

Children's Hospital Colorado, Aurora, Colorado

Children's National Medical Center, Washington D.C., District of Columbia

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

Dana-Farber Cancer Institute, Boston, Massachusetts

C.S. Mott Children's Hospital, Ann Arbor, Michigan

Duke University Health System, Durham, North Carolina

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Texas Children's Hospital, Houston, Texas

Seattle Children's Hospital, Seattle, Washington

Australia

Sydney Children's Hospital, Randwick, New South Wales

Queensland Children's Hospital, South Brisbane, Queensland

Royal Children's Hospital, Melbourne, Victoria

Perth Children's Hospital, Perth, Western Australia

Canada

The Hospital for Sick Children (SickKids), Toronto, Ontario

Montreal Children's Hospital, Montreal, Quebec

Germany

Hopp Children's Cancer Center at NCT Heidelberg (KiTZ), Heidelberg, Baden-Wurttemberg

Netherlands

Princess Máxima Center, Utrecht

New Zealand

Starship Children's Hospital, Auckland, Grafton

United Kingdom

Great Ormond Street Hospital, London